Kraig Biocraft Laboratories Nears Completion of Largest Production Batch of Parental Line Spider Silk Silkworms
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the near completion of its largest production batch of BAM-1 parental line spider silk silkworms. This milestone marks the achievement of true commercial-scale levels of parental strain production. The current batch is cocooning this week, with the production team reporting strong growth and great colony health.
CEO Kim Thompson states this production cycle will deliver the largest supply of BAM-1 production hybrid eggs in the company's history. This success verifies the scalability of Kraig Labs' spider silk technology, positioning the company to deliver commercial quantities to partners and customers. The results will supply Kraig Labs with millions of BAM-1 production hybrids for commercial production, marking a transition from development to a true production focus.
Positive
- Largest-ever production batch of BAM-1 parental line spider silk silkworms
- Achievement of commercial-scale levels of parental strain production
- Strong growth and great colony health reported in current production cycle
- Transition from development to true production focus
- Millions of BAM-1 production hybrids slated for commercial production
Negative
- None.
This Milestone marks the Achievement of True Commercial-scale Levels of Parental Strain Production
ANN ARBOR, Mich., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of commercially viable spider silk, is excited to announce that its current production batch is cocooning this week. This batch is the largest-scale production run of the BAM-1 parental lines in the Company's history.
This latest batch of silkworms is part of the Company’s ongoing expansion of its proprietary spider silk production technologies. The Company's production team and sericulture experts have been closely monitoring this production cycle and have reported strong growth and great colony health as Kraig Labs begins the cocooning process.
"We are very pleased with the progress of our current production cycle, which is on track to deliver the largest supply of BAM-1 production hybrid eggs in the Company's history," said Kim Thompson, CEO and founder of Kraig Labs. "The results we are seeing reflect our team's dedication to delivering truly cost-effective and commercially scalable spider silk production. This is a major step forward in commercializing spider silk technology, made possible by our new production center, and we look forward to utilizing this expanded production space to continue accelerating our plans for market entry."
The Company’s silkworms have been genetically engineered to produce recombinant spider silk at a level of efficiency and cost-effectiveness that was previously unattainable. This latest production run verifies the scalability of the Company's spider silk technology, positioning Kraig Labs to deliver commercial quantities of spider silk to its partners and customers.
With the near completion of this major production run, Kraig Labs has transitioned from a development and testing mindset to a true production focus. The results of this run will supply Kraig Labs with millions of BAM-1 production hybrids slated for commercial production.
"We are at an exciting and pivotal moment in Kraig Labs' history," Thompson added. "This successful production cycle is a testament to the hard work of our team and the power of our spider silk technologies. It underscores our commitment to unlocking the full potential of spider silk as an innovative material with limitless applications."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What milestone did Kraig Biocraft Laboratories (KBLB) recently achieve in spider silk production?
How many BAM-1 production hybrids will Kraig Biocraft Laboratories (KBLB) have for commercial production?
What does the recent production milestone mean for Kraig Biocraft Laboratories' (KBLB) business focus?
What is the significance of the BAM-1 parental line for Kraig Biocraft Laboratories (KBLB)?
